Rocket Pharmaceuticals Faces Securities Class Action Lawsuit Over Clinical Hold

Strategic Insights -

Rocket Pharmaceuticals, a biotechnology company developing gene therapies for rare diseases, has been sued by investors who claim the company misled them about the safety and progress of its critical RP-A501 gene therapy trial for Danon disease. The Securities and Exchange Commission (SEC) and investors have filed a class action lawsuit alleging that Rocket Pharmaceuticals failed to disclose significant protocol changes and known risks of Serious Adverse Events (SAEs), including patient deaths.

The lawsuit centers on whether the company provided materially false and misleading statements regarding the safety, efficacy, and clinical protocol of its RP-A501 Phase 2 pivotal trial. Plaintiffs allege that behind the scenes, Rocket had amended the study protocol months earlier to introduce a novel immunomodulatory agent in the trial's pretreatment regimen-an adjustment allegedly not disclosed to shareholders at the time.

Key Takeaways:

  • Rocket Pharmaceuticals' stock price plummeted 62% in a single day and down 75% from its February 27, 2025 closing price after the company revealed a clinical hold on the RP-A501 trial following a patient's SAE and subsequent death.
  • The class action complaint alleges that Rocket had amended the study protocol several months earlier to introduce a novel immunomodulatory agent without disclosing this to shareholders.
  • The lawsuit contends that Rocket's earlier statements created an artificially inflated stock price, and investors suffered heavy losses once the undisclosed risks and protocol changes became public.
  • The company told investors it had "made strong progress in advancing our gene therapy" and cited the Phase 1 results of RP-A501 as evidence of "safety and meaningful efficacy up to five years" on February 27, 2025.
  • The class period is from February 27, 2025 to May 26, 2025, and the lead plaintiff deadline is August 11, 2025.
  • The lawsuit is filed in New Jersey District Court as No. 3:25-cv-10049 (D. N.J.).
  • Hagens Berman is representing the plaintiffs and has filed the lawsuit on their behalf.

Statistics:

  • 62% decline in Rocket Pharmaceuticals' stock price on May 27, 2025 after the clinical hold announcement.
  • 75% decline in Rocket Pharmaceuticals' stock price from February 27, 2025 to May 27, 2025.
  • $9.40 per share closing price on February 27, 2025.
  • $3.41 per share closing price on May 27, 2025.
  • 14% return on investment (ROI) lost by shareholders in one trading day.

Sources:

  • Hagens Berman (newsfilecorp.com)
  • SEC Whistleblower program (sec.gov)
  • Rocket Pharmaceuticals, Inc. (nasdaq.com)
  • ClinicalTrials.gov (clinicaltrials.gov)